

### **Teradyne Reports Second Quarter 2022 Results**

July 26, 2022

- Revenue and earnings above the mid-point of Q2 guidance
- System Test, Wireless Test and Industrial Automation revenues grew compared with Q2'21 while Semiconductor Test declined consistent with guidance
- · Automotive and memory test demand strong while mobility and compute related demand softening
- Industrial Automation growth slowing

	Q2 <sup>-</sup> 22	Q2 <sup>-</sup> 21	Q1'22
Revenue (mil)	\$841	\$1,086	\$755
GAAP EPS	\$1.16	\$1.76	\$0.92
Non-GAAP EPS	\$1.21	\$1.91	\$0.98
Gross Margin	60.2%	59.6%	60.2%

NORTH READING, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- <u>Teradyne. Inc.</u> (NASDAQ: TER) reported revenue of \$841 million for the second quarter of 2022 of which \$541 million was in Semiconductor Test, \$135 million in System Test, \$64 million in Wireless Test and \$101 million in Industrial Automation (IA). GAAP net income for the second quarter was \$197.8 million or \$1.16 per diluted share. On a non-GAAP basis, Teradyne's net income in the second quarter was \$204.0 million, or \$1.21 per diluted share, which excluded acquired intangible asset amortization, restructuring and other charges, and included the related tax impact on non-GAAP adjustments.

"We delivered sales and earnings above the mid-point of our second quarter guidance on strong test group shipments despite supply shortages and slowing industrial automation growth," said Teradyne CEO Mark Jagiela. "As we enter Q3, we're lowering our shipment plan to align with reduced mobility related test demand, slower industrial automation growth, and continued supply shortages."

Guidance for the third quarter of 2022 is revenue of \$760 million to \$840 million, with GAAP net income of \$0.86 to \$1.12 per diluted share and non-GAAP net income of \$0.90 to \$1.16 per diluted share. Non-GAAP guidance excludes acquired intangible asset amortization.

#### Webcast

A conference call to discuss the second quarter results, along with management's business outlook, will follow at 8:30 a.m. ET, Wednesday, July 27. Interested investors should access the webcast at <a href="https://www.teradyne.com">www.teradyne.com</a> and click on "Investors" at least five minutes before the call begins. Presentation materials will be available starting at 8:30 a.m. ET. A replay will be available on the Teradyne website at <a href="https://investors.teradyne.com/events-presentations">https://investors.teradyne.com/events-presentations</a>.

#### **Non-GAAP Results**

In addition to disclosing results that are determined in accordance with GAAP, Teradyne also discloses non-GAAP results of operations that exclude certain income items and charges. These results are provided as a complement to results provided in accordance with GAAP. Non-GAAP income from operations and non-GAAP net income exclude acquired intangible assets amortization, restructuring and other, pension actuarial gains and losses, losses on convertible debt conversions, non-cash convertible debt interest, discrete income tax adjustments, and includes the related tax impact on non-GAAP adjustments. GAAP requires that these items be included in determining income from operations and net income. Non-GAAP income from operations, non-GAAP net income, non-GAAP income from operations as a percentage of revenue, non-GAAP net income as a percentage of revenue, and non-GAAP net income per share are non-GAAP performance measures presented to provide meaningful supplemental information regarding Teradyne's baseline performance before gains, losses or other charges that may not be indicative of Teradyne's current core business or future outlook. These non-GAAP performance measures are used to make operational decisions, to determine employee compensation, to forecast future operational results, and for comparison with Teradyne's business plan, historical operating results and the operating results of Teradyne's competitors. Non-GAAP diluted shares include the impact of Teradyne's call option on its shares. Management believes each of these non-GAAP performance measures provides useful supplemental information for investors, allowing greater transparency to the information used by management in its operational decision making and in the review of Teradyne's financial and operational performance, as well as facilitating meaningful comparisons of Teradyne's results in the current period compared with those in prior and future periods. A reconciliation of each available GAAP to non-GAAP financial measure discussed in this press release is contained in the attached exhibits and on the Teradyne website at www.teradyne.com by clicking on "Investor Relations" and then selecting "Financials" and the "GAAP to Non-GAAP Reconciliation" link. The non-GAAP performance measures discussed in this press release may not be comparable to similarly titled measures used by other companies. The presentation of non-GAAP measures is not meant to be considered in isolation, as a substitute for, or superior to, financial measures or information provided in accordance with GAAP.

### **About Teradyne**

Teradyne (NASDAQ:TER) brings high-quality innovations such as smart devices, life-saving medical equipment and data storage systems to market, faster. Its advanced test solutions for semiconductors, electronic systems, wireless devices and more ensure that products perform as they were designed. Its Industrial Automation offerings include collaborative and mobile robots that help manufacturers of all sizes improve productivity and lower costs. In 2021, Teradyne had revenue of \$3.7 billion and today employs over 6,300 people worldwide. For more information, visit teradyne.com. Teradyne<sup>®</sup> is a registered trademark of Teradyne, Inc. in the U.S. and other countries.

### Safe Harbor Statement

This release contains forward-looking statements regarding Teradyne's future business prospects, the impact of the global pandemic of the novel strain of the coronavirus (COVID-19), results of operations, market conditions, earnings per share, the impact of supply chain conditions on the

business, customer sales expectations, the payment of a quarterly dividend, the repurchase of Teradyne common stock pursuant to a share repurchase program, sanctions against Russia and Russian companies, and the impact of U.S. and Chinese export and tariff laws. Such statements are based on the current assumptions and expectations of Teradyne's management and are neither promises nor guarantees of future performance, events, customer sales, supply chain conditions or improvements, earnings per share, use of cash, payment of dividends, repurchases of common stock, payment of the senior convertible notes, the impact of the COVID-19 pandemic, sanctions against Russia and Russian companies, the impact of any tariffs or export controls imposed in the U.S. or China; compliance with trade protection measures or export restrictions; the impact of U.S. Department of Commerce or other government agency regulations relating to Huawei, HiSilicon and other customers or potential customers; or the impact of U.S. Department Commerce export control regulations for certain U.S. products and technology sold to military end users or for military end-use in China, Russia and Venezuela. There can be no assurance that management's estimates of Teradyne's future results or other forward-looking statements will be achieved. Specifically, Teradyne's 2024 earnings model is aspirational and includes many assumptions. There can be no assurance that these assumptions will be accurate or that model results will be achieved. As set forth below, there are many factors that could cause our 2024 earnings model and actual results to differ materially from those presently expected. Additionally, the current dividend and share repurchase programs may be modified, suspended or discontinued at any time.

Following Russia's invasion of Ukraine in February 2022, the U.S. and other countries imposed significant sanctions against the Russian government and many Russian companies and individuals. Although Teradyne does not have significant operations in Russia, the sanctions could impact Teradyne's business in other countries and could have a negative impact on the Company's supply chain, either of which could adversely affect Teradyne's business and financial results.

COVID-19 has resulted in authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, government vaccination mandates and other government regulations. These measures have impacted and may further impact Teradyne's workforce and operations, the operations of its customers, and those of its contract manufacturers and suppliers. As Teradyne implements measures to comply with additional regulations, the Company may experience increased compliance costs, increased risk of non-compliance and increased risk of employee attrition.

The COVID-19 pandemic has adversely impacted the Company's results of operations, including increased costs company-wide and constraints within the Company's supply chain. The Company cannot accurately estimate the amount of the impact on Teradyne's 2022 financial results and to its future financial results. The COVID-19 outbreak has significantly increased economic and demand uncertainty in Teradyne's markets. This uncertainty resulted in a significant decrease in demand for certain Teradyne products and could continue to impact demand for an uncertain period of time. The spread of COVID-19 has caused Teradyne to modify its business practices (including employee travel, employees working remotely, and cancellation of in person participation in meetings, events and conferences) and the Company may take further actions as may be required by government authorities or that it determines are in the best interests of its employees, customers, contract manufacturers and suppliers. There is uncertainty that such measures will be sufficient to mitigate the risks posed by the virus, and Teradyne's ability to perform critical functions could be impacted. The degree to which COVID-19 continues to impact Teradyne's results will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and continued spread of the virus, its severity, the actions to contain the virus or the availability and impact of vaccines in countries where the Company does business, and how quickly and to what extent normal economic and operating conditions can resume.

Important factors that could cause actual results, the 2024 earnings model, earnings per share, use of cash, dividend payments, repurchases of common stock, or payment of the senior convertible notes to differ materially from those presently expected include: conditions affecting the markets in which Teradyne operates; decreased or delayed product demand from one or more significant customers; development, delivery and acceptance of new products; the ability to grow the Industrial Automation business; increased research and development spending; deterioration of Teradyne's financial condition; the continued impact of the COVID-19 pandemic and related government responses on the market and demand for Teradyne's products, on its contract manufacturers and supply chain, and on its workforce; the impact of the global semiconductor supply shortage on our supply chain and contract manufacturers; the consummation and success of any mergers or acquisitions; demand for products by the Company's largest customers; unexpected cash needs; insufficient cash flow to make required payments and pay the principal amount on the senior convertible notes; the business judgment of the board of directors that a declaration of a dividend or the repurchase of common stock is not in the Company's best interests; additional U.S. tax regulations or IRS guidance; the impact of any tariffs or export controls imposed in the U.S. or China; compliance with trade protection measures or export restrictions; the impact of U.S. Department of Commerce or other government agency regulations relating to Huawei, HiSilicon and other customers or potential customers; the impact of U.S. Department Commerce export control regulations for certain U.S. products and technology sold to military end users or for military end-use in China, Russia and Venezuela; sanctions imposed against the Russian government and certain Russian companies and individuals by the U.S., and other countries; and other events, factors and risks disclosed in filings with the SEC, including, but not limited to, the "Risk Factors" sections of Teradyne's Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the fiscal quarter ended April, 3, 2022. The forward-looking statements provided by Teradyne in this press release represent management's views as of the date of this release. Teradyne anticipates that subsequent events and developments may cause management's views to change. However, while Teradyne may elect to update these forward-looking statements at some point in the future, Teradyne specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Teradyne's views as of any date subsequent to the date of this release.

### TERADYNE, INC. REPORT FOR SECOND FISCAL QUARTER OF 2022

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	<b>Quarter Ended</b>	Six Months Ended			
July 3,	April 3,	July 4,	July 3,	July 4,	
2022	2022	2021	2022	2021	

		Ψ	0.0,.00	Ψ.	. 00,0.0	Ψ	.,000,. =0	Ψ.	.,000,.00	Ψ.	.,00.,00.
	ost of revenues (exclusive of acquired intangible assets mortization shown separately below) (1)		334,377		300,437		438,739		634,814		758,727
Gross	s profit		506,389		454,933		646,989		961,322		1,108,607
Opera	ating expenses:										
S	elling and administrative		139,533		140,185		140,187		279,718		269,984
Е	ngineering and development		111,951		108,116		110,021		220,067		210,423
Α	cquired intangible assets amortization		4,871		5,063		5,402		9,934		10,938
R	estructuring and other (2)		2,044		15,714		2,507		17,758		(4,623)
	Operating expenses		258,399		269,078		258,117		527,477		486,722
ncon	ne from operations		247,990		185,855		388,872		433,845		621,885
In	nterest and other expense (3)		9,398		5,496		4,846	. <u> </u>	14,894	. <u> </u>	13,866
ncon	ne before income taxes		238,592		180,359		384,026		418,951		608,019
In	ncome tax provision		40,805		18,431		55,707		59,236		74,188
√et ir	ncome	\$	197,787	\$	161,928	\$	328,319	\$	359,715	\$	533,831
let ir	ncome per common share:										
Basic		\$	1.24	\$	1.00	\$	1.98	\$	2.24	\$	3.21
Dilute	ed	\$	1.16	\$	0.92	\$	1.76	\$	2.07	\$	2.85
Veigl	hted average common shares - basic		159,563		162,048		165,995		160,805		166,243
Veigl	hted average common shares - diluted (4)		171,159		175,575		186,750		173,367		187,245
Cash	dividend declared per common share	\$	0.11	\$	0.11	\$	0.10	\$	0.22	\$	0.20
(1)	Cost of revenues includes:			0	arter Endec				Six Mont	he l	Ended
(')	Cost of revenues modules.		July 3,	<del>Q</del> u	April 3,	•	July 4,		July 3,		July 4,
	Provision for excess and obsolete inventory	\$	<b>2022</b> 5,105	\$	<b>2022</b> 1,590	\$	<b>2021</b> 798	\$	<b>2022</b> 6,695	\$	<b>2021</b> 3,625
	Sale of previously written down inventory		(449)	·	(262)	·	(428)		(711)	·	(1,218)
	care or promotely minor assumments,	\$	4,656	\$	1,328	\$	370	\$	5,984	\$	2,407
2)	Restructuring and other consists of:			Qu	arter Endec	ı			Six Mont	ths E	Ended
			July 3, 2022		April 3, 2022		July 4, 2021		July 3, 2022		July 4, 2021
	Employee severance	\$	383	\$	551	\$	436	\$	934	\$	624
	Litigation settlement	•	-		14,700		-		14,700		_
	Acquisition related expenses and compensation		_		(201)		275		(201)		38
	Contingent consideration fair value adjustment		_		-		_		-		(7,227)
	Other		1,661		664		1,796		2,325		1,942
	- C.I.O.	\$	2,044	\$	15,714	\$	2,507	\$	17,758	\$	(4,623)
(3)	Interest and other includes:			Qu	arter Endec	ı			Six Mont	ths E	Ended
-			July 3, 2022		April 3, 2022		July 4, 2021		July 3, 2022		July 4, 2021
	Non-cash convertible debt interest	\$	-	\$	-	\$	3,277	\$	-	\$	6,858
	Loss on convertible debt conversions	Ψ	_	Ψ	_	Ψ	1,175	Ψ	_	Ψ	5,244
	Pension actuarial gains		_		_		(627)		_		(627)
	i onson actualiai gains	\$		\$	_	\$	3,825	\$	_	\$	11,475
		Ф	-	Φ	-	Φ	ა,ბ∠ე	Φ	-	Φ	11,4/0

840,766 \$

755,370 \$ 1,085,728 \$ 1,596,136 \$ 1,867,334

Net revenues

<sup>(4)</sup> Under GAAP, when calculating diluted earnings per share, convertible debt must be assumed to have converted if the effect on EPS would be dilutive. Diluted shares assume the conversion of the convertible debt as the effect would be dilutive. Accordingly, for the quarters ended July 3, 2022, April 3, 2022 and July 4, 2021, 1.9 million, 2.5 million and 9.6 million shares, respectively, have been included in diluted shares. For the

six months ended July 3, 2022 and July 4, 2021, 2.2 million and 9.9 million shares, respectively, have been included in diluted shares. For the quarters ended July 3, 2022, April 3, 2022 and July 4, 2021, diluted shares also included 9.0 million, 10.0 million and 10.1 million shares, respectively, from the convertible note hedge transaction. For the six months ended July 3, 2022 and July 4, 2021, diluted shares included 9.5 million and 9.8 million shares, respectively, from the convertible note hedge transaction.

### CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)

		July 3, 2022		December 31, 2021
Assets				
Cash and cash equivalents	\$	572,023	\$	1,122,199
Marketable securities		209,846		244,231
Accounts receivable, net		683,739		550,749
Inventories, net		295,625		243,330
Prepayments		498,093		406,266
Other current assets	_	11,109		9,452
Total current assets		2,270,435		2,576,227
Property, plant and equipment, net		411,263		387,240
Operating lease right-of-use assets, net		71,812		68,807
Marketable securities		111,999		133,858
Deferred tax assets		126,639		102,428
Retirement plans assets		14,245		15,110
Other assets		26,942		24,096
Acquired intangible assets, net		62,509		75,635
Goodwill	_	397,733	_	426,024
Total assets	\$	3,493,577	\$	3,809,425
Liabilities				
Accounts payable	\$	175,606	\$	153,133
Accrued employees' compensation and withholdings		190,506		253,667
Deferred revenue and customer advances		163,127		146,185
Other accrued liabilities		133,881		124,187
Operating lease liabilities		17,770		19,977
Income taxes payable		106,863		88,789
Current debt		9,632		19,182
Total current liabilities		797,385		805,120
Retirement plans liabilities		141,884		151,141
Long-term deferred revenue and customer advances		50,357		54,921
Long-term other accrued liabilities		15,530		15,497
Deferred tax liabilities		3,143		6,327
Long-term operating lease liabilities		62,751		56,178
Long-term income taxes payable		59,135		67,041
Debt	_	64,796	_	89,244
Total liabilities	_	1,194,981	_	1,245,469
Mezzanine equity		-		1,512
Shareholders' equity		2,298,596	_	2,562,444
Total liabilities, convertible common shares and shareholders' equity	\$	3,493,577	\$	3,809,425

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)

Quarte	r Ended	Six Months Ended			
July 3,	July 4,	July 3,	July 4,		
2022	2021	2022	2021		

Net income	\$	197,787	\$	328,319	\$	359,715	\$	533,831
Adjustments to reconcile net income to net cash provided by operating activities:								
Depreciation		21,957		21,938		44,460		45,848
Stock-based compensation		12,228		10,999		25,122		23,231
Amortization		4,862		9,521		10,095		19,343
Provision for excess and obsolete inventory		5,105		798		6,695		3,625
Deferred taxes		(34,885)		257		(23,597)		(800)
Losses (gains) on investments		6,972		(2,159)		8,973		(4,650)
Retirement plans actuarial gains		-		(627)		-		(627)
Contingent consideration fair value adjustment		-		-		-		(7,227)
Loss on convertible debt conversions		-		1,175		-		5,244
Other		345		(1)		522		199
Changes in operating assets and liabilities								
Accounts receivable		(146,592)		(285,186)		(146,384)		(372,698)
Inventories		(37,202)		56,320		(46,682)		19,908
Prepayments and other assets		(25,597)		(31,285)		(99,902)		(117,416)
Accounts payable and other liabilities		85,922		97,361		(38,460)		86,790
Deferred revenue and customer advances		7,416		7,237		14,163		15,189
Retirement plans contributions		(1,289)		(814)		(2,618)		(2,739)
Income taxes		18,426	_	(7,569)		10,815		(2,628)
Net cash provided by operating activities		115,455		206,284		122,917		244,423
Cash flows from investing activities:								
Purchases of property, plant and equipment		(45,744)		(34,707)		(89,743)		(73,957)
Purchases of marketable securities		(81,904)		(186,482)		(247,881)		(398,086)
Proceeds from maturities of marketable securities		42,970		265,985		139,652		460,213
Proceeds from sales of marketable securities		113,061		54,819		143,642		116,112
Purchase of investment				(12,000)		-		(12,000)
Net cash provided by (used for) investing activities		28,383		87,615		(54,330)	_	92,282
Cash flows from financing activities:								
Issuance of common stock under stock purchase and stock								
option plans		61		15,437		16,536		32,581
Repurchase of common stock		(331,334)		(151,396)		(532,799)		(196,584)
Dividend payments		(17,547)		(16,604)		(35,442)		(33,271)
Payments of convertible debt principal		(21,598)		(15,553)		(42,292)		(66,828)
Payments related to net settlement of employee stock		(4.700)		(4.440)		(20.700)		(04.704)
compensation awards		(1,732)	_	(1,119)	_	(32,780)		(31,794)
Net cash used for financing activities		(372,150)		(169,235)		(626,777)		(295,896)
Effects of exchange rate changes on cash and cash equivalents		5,732		(1,372)		8,014		(489)
Decrease (increase) in cash and cash equivalents	-	(222,580)		123,292		(550,176)		40,320
Cash and cash equivalents at beginning of period		794,603		831,149		1,122,199		914,121
Cash and cash equivalents at end of period	\$	572,023	\$	954,441	\$	572,023	\$	954,441

GAAP to Non-GAAP Earnings Reconciliation

(In millions, except per share amounts)

	Quarter Ended								
	July 3, % of Net 2022 Revenues	April 3, % of Net 2022 Revenues	July 4, % of Net 2021 Revenues						
Net revenues	\$ 840.8	\$ 755.4	\$1,085.7						

Gross profit GAAP and non-GAAP \$ 506.4	60.2%	\$ 454.9	60.2%	\$ 647.0	59.6%
Income from operations - GAAP \$ 248.0	29.5%	\$ 185.9	24.6%	\$ 388.9	35.8%
Restructuring and other (1) 2.0	0.2%	15.7	2.1%	2.5	0.2%
Acquired intangible assets amortization 4.9	0.6%	5.1	0.7%	5.4	0.5%
Income from operations - non-GAAP\$ 254.9	30.3%	\$ 206.7	27.4%	\$ 396.8	36.5%

			per Co	ncome ommon nare			per Co	ncome ommon nare			per Co	ncome ommon nare
	July 3, 2022	% of Net Revenues	Basic	Diluted	April 3, 2022	% of Net Revenues	Basic	Diluted	July 4, 2021	% of Net Revenues	Basic	Diluted
Net income - GAAP	\$ 197.8	23.5%	\$ 1.24	\$ 1.16	\$ 161.9	21.4%	\$ 1.00	\$ 0.92	\$ 328.3	30.2%	\$ 1.98	\$ 1.76
Restructuring and other (1) Acquired intangible	2.0	0.2%	0.01	0.01	15.7	2.1%	0.10	0.09	2.5	0.2%	0.02	0.01
assets amortization	4.9	0.6%	0.03	0.03	5.1	0.7%	0.03	0.03	5.4	0.5%	0.03	0.03
Loss on convertible debt conversions (2) Interest and other	-	-	-	-	-	-	-	-	1.2	0.1%	0.01	0.01
(2)	-	-	-	-	-	-	-	-	3.3	0.3%	0.02	0.02
Pension mark-to- market adjustment									(0.6)	0.40/	(0.00)	(0.00)
(2)	-	-	-	-	-	-	-	-	(0.6)	-0.1%	(0.00)	(0.00)
Exclude discrete tax adjustments Non-GAAP tax	1.6	0.2%	0.01	0.01	(10.4)	-1.4%	(0.06)	(0.06)	(1.1)	-0.1%	(0.01)	(0.01)
adjustments	(2.3)	-0.3%	(0.01)	(0.01)	(3.3)	-0.4%	(0.02)	(0.02)	(1.5)	-0.1%	(0.01)	(0.01)
Convertible share adjustment (3)	-	-	-	0.01	_	_	_	0.01	_	-	_	0.10
Net income -		-										
	\$ 204.0	24.3%	\$ 1.28	\$ 1.21	\$ 169.0	22.4%	\$ 1.04	\$ 0.98	\$ 337.5	31.1%	\$ 2.03	\$ 1.91
GAAP and non-GAAP weighted average												
common shares - basic GAAP weighted	159.6				162.0				166.0			
average common shares - diluted	171.2				175.6				186.8			
Exclude dilutive shares related to convertible note transaction Non-GAAP weighted average common	(1.9)				(2.5)				(9.6)			
shares - diluted	169.3				173.1				177.2			
(4) Destructuries												

# (1) Restructuring and other consists of:

			Quarter Ended	
		uly 3, 2022	April 3, 2022	July 4, 2021
Employee				
severance	\$	0.4	\$ 0.6	\$ 0.4
Litigation settle	ment	-	14.7	-
Acquisition rela	ated			
compensation		-	(0.2)	0.3
Other		1.7	0.7	1.8

- (2) For the quarter ended July 4, 2021, adjustment to exclude loss on convertible debt conversions. For the quarter ended July 4, 2021, Interest and other included non-cash convertible debt interest expense. For the quarter ended July 4, 2021, adjustments to exclude actuarial (gain) loss recognized under GAAP in accordance with Teradyne's mark-to-market pension accounting.
- (3) For the quarters ended July 3, 2022, April 3, 2022, and July 4, 2021, the non-GAAP diluted EPS calculation adds back \$0.2 million, \$0.3 million, and \$0.9 million, respectively, of convertible debt interest expense to non-GAAP net income. For the quarters ended July 3, 2022, April 3, 2022, and July 4, 2021, non-GAAP weighted average diluted common shares include 9.0 million, 10.0 million and 10.1 million shares, respectively, from the convertible note hedge transaction.

			Six Months Ended	
	July 3, 2022	% of Net Revenues	July 4, 2021	% of Net Revenues
Net Revenues	\$1,596.1		\$1,867.3	
Gross profit GAAP and	t			
non-GAAP	\$ 961.3	60.2%	\$1,108.6	59.4%
Income from				
operations - GAAP	\$ 433.8	27.2%	\$ 621.9	33.3%
Restructuring and other (1)	17.8	1.1%	(4.6)	-0.2%
Acquired intangible assets amortization		0.6%	10.9	0.6%
Income from operations - non-GAAF	P\$ 461.5	28.9%	\$ 628.2	33.6%

				per Co	ncome ommon are				per Co	ncome ommon are
	•	July 3, 2022	% of Net Revenues	Basic	Diluted	•	July 4, 2021	% of Net Revenues	Basic	Diluted
Net income - GAAP	\$	359.7	22.5%	\$ 2.24	\$ 2.07	\$	533.8	28.6%	\$ 3.21	\$ 2.85
Restructuring and		47.0	4 404	0.44	0.40		(4.0)	0.007	(0.00)	(0.00)
other (1)		17.8	1.1%	0.11	0.10		(4.6)	-0.2%	(0.03)	(0.02)
Acquired intangible assets amortization		9.9	0.6%	0.06	0.06		10.9	0.6%	0.07	0.06
Loss on convertible debt conversions										
(2)		-	-	-	-		5.2	0.3%	0.03	0.03
Interest and other (2)		-	-	-	-		6.9	0.4%	0.04	0.04
Pension mark-to- market adjustment										
(2)		-	-	-	-		(0.6)	-0.0%	(0.00)	(0.00)
Exclude discrete tax		(0.0)	0.00/	(0.05)	(0.05)		(40.0)	0.00/	(0.40)	(0.00)
adjustments Non-GAAP tax		(8.8)	-0.6%	(0.05)	(0.05)		(16.3)	-0.9%	(0.10)	(0.09)
adjustments		(5.6)	-0.4%	(0.03)	(0.03)		(1.9)	-0.1%	(0.01)	(0.01)
Convertible share adjustment (3)					0.03					0.16
Net income - non-GAAP	\$	373.0	23.4%	\$ 2.32	\$ 2.18	\$	533.4	28.6%	\$ 3.21	\$ 3.02
GAAP and non-GAAP										
weighted average common shares - basic	:	160.8					166.2			
GAAP weighted average common										
average common										

187.2

shares - diluted

173.4

Exclude dilutive shares from convertible note	(2.2)	(9.9)
Non-GAAP weighted		
average common shares - diluted	171.2	177.3

(1) Restructuring and other consists of:

_		Six Months Ended	
	July 3, 2022		uly 4, 2021
Litigation settlement \$	14.7		\$ -
Employee			
severance	0.9		0.6
Acquisition related			
expenses and			
compensation	(0.2)		-
Contingent			
consideration fair			
value adjustment	-		(7.2)
Other _	2.3		 1.9
9	17.8		\$ (4.6)

- (2) For the six months ended July 4, 2021, adjustment to exclude loss on convertible debt conversions. For the six months ended July 4, 2021, Interest and other included non-cash convertible debt interest expense. For the six months ended July 4, 2021, adjustments to exclude actuarial (gain) loss recognized under GAAP in accordance with Teradyne's mark-to-market pension accounting.
- (3) For the six months ended July 3, 2022 and July 4, 2021, the non-GAAP diluted EPS calculation adds back \$0.5 million and \$2.1 million, respectively, of convertible debt interest expense to non-GAAP net income. For the six months ended July 3, 2022 and July 4, 2021, non-GAAP weighted average diluted common shares include 9.5 million and 9.8 million shares, respectively, related to the convertible debt hedge transaction.

### GAAP to Non-GAAP Reconciliation of Third Quarter 2022 guidance:

GAAP and non-GAAP		
third quarter revenue	\$760	\$840
guidance:	milliont	o million
GAAP net income per		
diluted share	\$ 0.86	\$ 1.12
Exclude acquired		
intangible assets		
amortization	0.03	0.03
Convertible share		
adjustment	 0.01	0.01
Non-GAAP net income		
per diluted share	\$ 0.90	\$ 1.16

For press releases and other information of interest to investors, please visit Teradyne's homepage at <a href="http://www.teradyne.com">http://www.teradyne.com</a>.

Contact: Teradyne,

Inc.

Andy Blanchard 978-370-2425 Vice President of Corporate Relations



Source: Teradyne, Inc.